Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 3/20 | 0.45 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.40 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.40 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.40 |
| ▸ | PRKAA1 | Q13131 | 2/20 | 0.40 |
| ▸ | PRKAG3 | Q9UGI9 | 2/20 | 0.40 |
| ▸ | PRKAG2 | Q9UGJ0 | 2/20 | 0.40 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.40 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.39 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 7/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4224615 | 0.90 | AQP1 (0.55) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4768274 | 0.88 | AQP1 (0.57) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4768198 | 0.88 | AQP1 (0.42) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4234537 | 0.85 | PRKAB2 (0.41) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4230246 | 0.84 | AQP1 (0.41) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4221743 | 0.84 | AQP1 (0.46) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL27728290 | 0.84 | AQP1 (0.48) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4225586 | 0.84 | AQP1 (0.46) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4225950 | 0.84 | AQP1 (0.53) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 | |
| SCHEMBL4219183 | 0.82 | AQP1 (0.65) | AQP1PRKAB2PRKAG1PRKAA2PRKAA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | claimed |
| US-7396857-B2 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2008-07-08 | — | — | US | claimed |
| EP-1871354-A1 | TREATMENT OF PAIN | Wyeth (US) | 2008-01-02 | — | — | EP | claimed |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| JP-2007509174-A | — | — | 2007-04-12 | — | — | JP | claimed |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258711-A1 | Treatment of drug abuse | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| US-20060258713-A1 | Treatment of pain | WYETH (US) | 2006-11-16 | — | — | US | claimed |
| WO-2006116171-A1 | TREATMENT OF PAIN | WYETH (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1675840-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | Wyeth a Corporation of the State of Delaware (US) | 2006-07-05 | — | — | EP | claimed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | claimed |
| WO-2005044812-A1 | DIHYDROBENZOFURANYL ALKANAMINE DERIVATIVES AS 5HT2C AGONISTS | WYETH A CORPORATION OF THE STATE OF DELAWARE (US) | 2005-05-19 | — | — | WO | claimed |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | WYETH (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080269321-A1 | Therapeutic Combinations for the Treatment or Prevention of Depression | WYETH (US) | 2008-10-30 | — | — | US | disclosed |
| US-7435837-B2 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2008-10-14 | — | — | US | disclosed |
| WO-2006116149-A1 | NEW THERAPEUTIC COMBIANATIONS FOR THE TREATMENT OR PREVENTION OF DEPRESSION | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258715-A1 | Therapeutic combinations for the treatment or prevention of depression | GRIN3A, GRIN2A, BDNF | AQP1 3262/4885PRKAB2 3384/4885PRKAG1 3443/4885 |
| US-20060258639-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | TTPA, GAP43, SLC6A3 | AQP1 1709/4885PRKAB2 3768/4885PRKAG1 3769/4885 |
| US-20060258711-A1 | Treatment of drug abuse | OPRK1, OPRM1, ADH1A | AQP1 1478/4885PRKAB2 2840/4885PRKAG1 2552/4885 |
| US-20070225334-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | AQP1 1312/4885PRKAB2 2928/4885PRKAG1 3153/4885 |
| US-20060258739-A1 | Dihydrobenzofuran derivatives and uses therof | HTR1F, HTR2C, HTR3D | AQP1 3184/4885PRKAB2 4363/4885PRKAG1 4343/4885 |
| US-20090082434-A1 | Dihydrobenzofuranyl Alkanamine Derivatives and Methods for Using Same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885PRKAB2 2598/4885PRKAG1 2441/4885 |
| US-20060258713-A1 | Treatment of pain | OPRL1, OPRK1, OPRD1 | AQP1 694/4885PRKAB2 2785/4885PRKAG1 2694/4885 |
| US-20080269321-A1 | Therapeutic Combinations for the Treatment or Prevention of Depression | GRIN3A, GRIN2A, BDNF | AQP1 3262/4885PRKAB2 3384/4885PRKAG1 3443/4885 |
| US-20050143452-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | HTR2C, HTR1A, HTR3A | AQP1 1105/4885PRKAB2 2598/4885PRKAG1 2441/4885 |
| US-20050261347-A1 | Dihydrobenzofuranyl alkanamine derivatives and methods for using same | ADRA2A, HTR2A, ADRA1A | AQP1 2290/4885PRKAB2 2184/4885PRKAG1 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.